Login to Your Account

NPS Reclaims Rights to 2 Drugs From Takeda in $50M Stock Deal

By Catherine Shaffer
Staff Writer

Tuesday, March 19, 2013
NPS Pharmaceuticals Inc. regained full worldwide rights to teduglutide (Gattex) and recombinant human parathyroid hormone 1-84 (PTH 1-84/Preotact) from Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, in exchange for common stock valued at $50 million, plus a milestone payment of $30 million in cash or stock in the first year that net sales of both products exceed $750 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription